Medicare Spending on Drugs With Accelerated Approval, 2015-2019.
Journal
JAMA health forum
ISSN: 2689-0186
Titre abrégé: JAMA Health Forum
Pays: United States
ID NLM: 101769500
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
received:
09
08
2021
accepted:
08
10
2021
entrez:
17
8
2022
pubmed:
18
8
2022
medline:
18
8
2022
Statut:
epublish
Résumé
This article examines the budgetary implications of high-priced accelerated approval drugs by estimating Medicare spending on these drugs from 2015 through 2019.
Identifiants
pubmed: 35977299
doi: 10.1001/jamahealthforum.2021.3937
pii: ald210024
pmc: PMC8796889
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Pagination
e213937Informations de copyright
Copyright 2021 Rome BN et al. JAMA Health Forum.
Déclaration de conflit d'intérêts
Conflict of Interest Disclosures: Dr Rome reported grants from Anthem Public Policy Institute and personal fees from Alosa Health and Blue Cross Blue Shield of Massachusetts outside the submitted work. Dr Feldman reported personal fees from Alosa Health, Aetion, and Blue Cross Blue Shield of Massachusetts, and grants from the US Food and Drug Administration Sentinel Initiative and National Institutes of Health outside the submitted work.
Références
N Engl J Med. 2017 May 25;376(21):2001-2004
pubmed: 28538133
JAMA. 2017 Aug 15;318(7):626-636
pubmed: 28810023
BMJ. 2021 Sep 8;374:n1959
pubmed: 34497044